AbbVie’s SKYRIZI® public coverage for the treatment of moderate to severe plaque psoriasis is now available in other jurisdictions

SKYRIZI® is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading the development and commercialization globally, and is the only IL-23 inhibitor to come to a successful conclusion with pCPA.

“I was lucky enough to be involved in clinical trials. SKYRIZI® has improved the quality of life of my psoriasis patients by offering them clear skin,” says Dr. Irina Turchin, MD, FRCPC, Fredericton, NB. “It is good to see that this treatment is now available for more patients in New Brunswick. “

Psoriasis is a chronic condition that affects 125 million people worldwide, including 1 million Canadians, and many patients still fail to achieve their goals despite treatment or lose response to treatment over time.2-4 The most common form is plaque psoriasis, which affects approximately 90% of patients. 5

“I am thrilled to be able to offer SKYRIZI® to patients with moderate to severe psoriasis in British Columbia as it is now listed in the Pharmacare provincial form. Having experience with the drug in clinical trials, I have personally seen how it provides long-lasting and comprehensive skin removal for many patients. Patients are particularly satisfied with the dosing schedule, ”explains Dr. Chih-ho Hong, MD, FRCPC, dermatologist.

Psoriasis has a genetic basis, and about one third of people with psoriasis have at least one family member with the disease. 5 Of note, the prevalence of psoriasis is 5 to 10 times greater in Newfoundland is Labrador than the rest of Canada. 6

“PsoriasisNL is pleased to hear of this list of another psoriasis treatment for patients in our province. We would like to thank the government of Newfoundland is Labrador for their continued support of advanced therapies for patients in this province suffering from severe psoriasis. As the province with the highest prevalence of this disease, the availability of these treatments has significantly increased the quality of life of psoriasis sufferers, “explains Deva Murthy, President of PsoriasisNL.

Information regarding specific reimbursement criteria can be found by consulting the links below:

SKYRIZI® is a new humanized immunoglobulin monoclonal antibody designed to selectively inhibit IL-23, a natural cytokine involved in inflammatory and immune responses.1 On April 17, 2019, SKYRIZI ™ has received a NOC from Health Canada for the treatment of moderate to severe plaque psoriasis in patients who are candidates for systemic therapy or phototherapy, based on the results of clinical studies showing significant improvement in skin clearance levels after just 16 weeks and 52 weeks with administration every 3 months in more than 2000 adult patients.1 Four pivotal phase 3 studies, ultIMMa-1, ultIMMa-2, IMMvent and IMMhance evaluated more than 2,000 patients with moderate to severe plaque psoriasis.4 Canadians living with moderate to severe plaque psoriasis were well represented in all four pivotal clinical trials leading to Health Canada’s approval, demonstrating Canadian leadership in this clinical development program.

About AbbVie in Dermatology
For more than a decade, AbbVie has worked to discover new solutions and improve care for people with severe skin conditions. With an extensive clinical trial program, we continue to actively research and adapt to the ever-changing needs of the dermatology community and advance our pipeline to help people reach their treatment goals and live beyond their skin disease.

About AbbVie Care
The AbbVie Care program is designed to provide a wide range of personalized services, including reimbursement and financial support, pharmacy services, lab work reminder and coordination, personalized training and disease management support throughout the treatment journey. For more information, see

About AbbVie
AbbVie’s mission is to discover and deliver innovative medicines that solve serious health problems today and address the medical challenges of tomorrow. We strive to make a major impact on people’s lives in several key therapeutic areas: Immunology, Oncology, Neuroscience, Eye Care, Virology, Women’s Health and Gastroenterology, as well as products and services across its Allergan Aesthetics portfolio. For more information on AbbVie, visit and Follow @abbvieCanada is @abbvie on Twitter or view careers on our Facebook or LinkedIn page.



SKYRIZI® (risankizumab) [Canadian Product Monograph]. AbbVie Corporation, April 17, 2019.


International Federation of Psoriasis Associations. Accessed March 22, 2019. Available at:


Mroweitz, U., et al. Setting treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011 Jan; 303 (1): 1–10.


Levin, et al. Biological fatigue in psoriasis. J Dermatolog Treat. 2014 February; 25 (1): 78-82. doi: 10.3109 / 09546634.2013.826341.


Canadian Dermatology Association – Psoriasis. Accessed September 30, 2020.


Nall, L., Gulliver, W., Charmley, P., and Farber, EM (1999) Search for the Psoriasis Susceptibility Gene: The Newfoundland Study. Cutis, 64, 323–329).

SOURCE AbbVie Canada

For More Information: Media: Kim Hogan, AbbVie Canada, (514) 832-7288, [email protected]



Leave a Reply

Your email address will not be published. Required fields are marked *